引用次数
引用: 3,266
H-指数: 26
I10-指数 : 64
出版物: 257
Methods & Materials
Seosamh McCauley , Karen Tumelty , Gerard G Hanna , Ruth L Eakin
Preclinical radiotherapy technology, dosimetry and treatment planning
K.M. Prise , K. Butterworth , A.R. Hounsell , S. Jain
Radiotherapy and Oncology 119
2016
Image-guided Radiotherapy to Manage Respiratory Motion: Lung and Liver.
J. Dhont , S.V. Harden , L.Y.S. Chee , K. Aitken
Clinical Oncology 32 ( 12) 792 -804
2
2020
Long-term Survival with 18-Fluorodeoxyglucose Positron Emission Tomography-directed Therapy in Non-small Cell Lung Cancer with Synchronous Solitary Brain Metastasis
S. Newman , N. Bucknell , M. Bressel , P. Tran
Clinical Oncology 33 ( 3) 163 -171
2021
Re: Lewis et al. Palliative Lung Radiotherapy: Higher Dose Leads to Improved Survival?
G.M. Walls , J. O'Hare , G.G. Hanna , R.L. Eakin
Clinical Oncology 33 ( 1)
2021
A Qualitative Assessment of Radiotherapy Training at a UK Regional Cancer Centre.
G.M. Walls , A.J. Cole , J.J. McAleer , G.G. Hanna
Clinical Oncology 33 ( 4) 261 -269
2021
The Impact of Colleague Peer Review on the Radiotherapy Treatment Planning Process in the Radical Treatment of Lung Cancer
K.P. Rooney , J. McAleese , C. Crockett , J. Harney
Clinical Oncology 27 ( 9) 514 -518
18
2014
Ninety-day mortality for radical lung radiotherapy
R. Evans , A. Cole , G.G. Hanna , J. McAleese
Clinical Oncology 28
2016
The Challenges Faced in Developing Novel Drug Radiation Combinations in Non-small Cell Lung Cancer.
S. Harrow , G.G. Hanna , C. Faivre-Finn , F. McDonald
Clinical Oncology 28 ( 11) 720 -725
6
2016
Radiotherapy and Immunotherapy Combinations in Non-small Cell Lung Cancer: A Promising Future?
G.G. Hanna , T. Illidge
Clinical Oncology 28 ( 11) 726 -731
7
2016
The Elderly are Less Likely to Receive Recommended Radical Radiotherapy for Non-small Cell Lung Cancer
J. McAleese , S. Baluch , K. Drinkwater , P. Bassett
Clinical Oncology 29 ( 9) 593 -600
15
2017
Oligoprogressive Oncogene-addicted Lung Tumours: Does Stereotactic Body Radiotherapy Have a Role? Introducing the HALT Trial.
F. McDonald , G.G. Hanna
Clinical Oncology 30 ( 1) 1 -4
10
2018
Re-irradiation for Locally Recurrent Lung Cancer: Evidence, Risks and Benefits
R. Rulach , G.G. Hanna , K. Franks , J. McAleese
Clinical Oncology 30 ( 2) 101 -109
12
2018
UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy.
G.G. Hanna , L. Murray , R. Patel , S. Jain
Clinical Oncology 30 ( 1) 5 -14
69
2018
Referrals Patterns to an Oncology Clinical Advice Service
G.M. Walls , J. McAleese , G.G. Hanna
Clinical Oncology 30 ( 6) 395 -396
2018
UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy: Reply to Ghafoor et al.
G.G. Hanna , F. McDonald , L. Murray , S. Harrow
Clinical Oncology 30 ( 7) 456
3
2018
Risk of Death from Pneumocystis jirovecii after Curative-intent Radiotherapy for Lung Cancer.
J. McAleese , L. Mooney , G.M. Walls , R.L. Eakin
Clinical Oncology 30 ( 12)
1
2018
The Abscopal Effect of Stereotactic Radiotherapy and Immunotherapy: Fool's Gold or El Dorado?
D. Xing , S. Siva , G.G. Hanna
Clinical Oncology 31 ( 7) 432 -443
50
2019
Differential Relapse Patterns for Non-small Cell Lung Cancer Subtypes Adenocarcinoma and Squamous Cell Carcinoma: Implications for Radiation Oncology
J. McAleese , A. Taylor , G.M. Walls , G.G. Hanna
Clinical Oncology 31 ( 10) 711 -719
4
2019
Curative Radiotherapy for Lung Cancer in the UK: International Benchmarking
J. McAleese , C.M. Rooney , S. Baluch , K.J. Drinkwater
Clinical Oncology 31 ( 10) 731
2019
fiona mcdonald Suneil Jain Joe M. O'Sullivan Shankar Siva Aidan Cole Michael MacManus Corinne Faivre-Finn Conor K McGarry Susan Harden David Eaton Kevin M. Prise VP Cosgrove dean fennell Christian Ottensmeier S Senan Dr Gerard M Walls MB MRCP MSc FRCR PhD Daniela Thorwarth Sarah O S Osman Emma Kirkpatrick Vincent GREGOIRE